Prophylaxis: Chloroquine or hydroxychloroquine prevention of COVID-19 disease for caregivers in L...
The aim of this clinical trial is to determine if prophylactic chloroquine or hydroxychloroquine prevents symptomatic COVID-19 illness health care workers in Luxembourg. The secondary objectives include: • Attenuation of the clinical severity of COVID-19 infections. • The prevention of asymptomatic COVID-19. • The prevention of symptomatic all-cause acute respiratory illnesses (ARI).
COVID19-induced changes to the plasma proteome
Studies focussing on human coronavirus found so far seven different viruses including SARS, MERS and COVID19. SARS, MERS and COVID19 present with various flu-like symptoms up to respiratory distress. Secondary symptoms include kidney problems, cardiovascular problems and neurological signs, like headache and nausea. In the case of the SARS infection, it has been shown that the virus can invade the central nervous system in patients and laboratory animals. The infection of epithelial cells by a coronavirus will lead to a change of the cellular protein composition in response to the virus' ...
Development of a MS-based COVID19 test
The project aims on developing an alternative test for the detection of corona virae based on proteomic methods. The advatage of the use of proteins is that the samples do not have to be cooled and can be transported at room temperature to the analytical lab.
Preventing fatal complications of COVID-19 with novel SkQ1 treatment
Accumulating evidence suggests that a subgroup of patients with severe COVID-19 might have a cytokine storm syndrome that leads to hyperinflammation of their lung tissue. Challenge is how to interrupt this hyperinflammation without critically suppressing immune system. SkQ1 compound developed by Mitotech SA (Luxembourg) has shown to interrupt cytokine storm in animal models and may be irreplaceable in preventing fatalities in COVID-19.